calcitonin salmon

FDA Drug Profile — calcitonin salmon, Calcitonin Salmon, Miacalcin

calcitonin salmon is listed in the FDA National Drug Code directory with 5 NDC codes, marketed under brand names including calcitonin salmon, Calcitonin Salmon, Miacalcin. Available dosage form: injection, solution.

Drug details

Generic Name
calcitonin salmon
Brand Names
calcitonin salmon, Calcitonin Salmon, Miacalcin
Application Number
ANDA216294
Sponsor
Amneal Pharmaceuticals LLC
NDC Codes
5
Dosage Forms
INJECTION, SOLUTION
Routes
INTRAMUSCULAR, SUBCUTANEOUS
Active Ingredients
CALCITONIN SALMON

Indications and Usage

1 INDICATIONS AND USAGE Calcitonin Salmon (synthetic origin) Nasal Spray is a calcitonin, indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.1 ) Limitations of Use: Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.2 , 5.4 ) Calcitonin salmon nasal spray has not been shown to increase bone mineral density in early postmenopausal women ( 1.2 ) 1.1 Treatment of Postmenopausal Osteoporosis Calcitonin Salmon (synthetic origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. Fracture reduction efficacy has not been demonstrated. Calcitonin Salmon (synthetic origin) Nasal Spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). 1.2 Important Limitations of Use Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see Warnings and Precautions (5.4)] . Calcitonin Salmon (synthetic origin) Nasal Spray has not been shown to increase spinal bone mineral density in early postmenopausal women.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.